Atomoxetine drug class
Pro Research Analysisby 
Searched over 200M research papers
Atomoxetine Drug Class: A Comprehensive Overview
Introduction to Atomoxetine: Nonstimulant ADHD Treatment
Atomoxetine, marketed under the brand name Strattera, is a selective norepinephrine reuptake inhibitor (NRI) used primarily for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children, adolescents, and adults Kratochvil2003Fu2022Corman2004. Unlike traditional stimulant medications for ADHD, such as methylphenidate, atomoxetine is a nonstimulant, making it a unique option for patients who may not respond well to or cannot tolerate stimulant medications Kratochvil2002Simpson2004Corman2004.
Mechanism of Action: Selective Norepinephrine Reuptake Inhibition
Atomoxetine works by selectively inhibiting the presynaptic norepinephrine transporter, which increases the levels of norepinephrine in the brain. This action helps improve attention and reduce hyperactive and impulsive behaviors associated with ADHD Spencer2002Fu2022Weintraub2010. Additionally, atomoxetine has minimal affinity for other neurotransmitter transporters or receptors, which contributes to its specific action profile Spencer2002Fu2022.
Clinical Efficacy: Comparable to Stimulants
Multiple studies have demonstrated the efficacy of atomoxetine in treating ADHD symptoms. Clinical trials have shown that atomoxetine significantly reduces ADHD symptoms as measured by various rating scales, such as the ADHD-IV Rating Scale and the Conners Adult ADHD Rating Scale (CAARS) Kratochvil2002Kratochvil2003Spencer2002. In head-to-head comparisons, atomoxetine has been found to have therapeutic effects comparable to those of methylphenidate, a commonly used stimulant .
Safety and Tolerability: A Well-Tolerated Option
Atomoxetine is generally well tolerated, with a safety profile that has been extensively studied over the years. Common side effects include dry mouth, insomnia, nausea, decreased appetite, and dizziness, but these are typically mild to moderate and transient Reed2015Simpson2004Corman2004. Long-term safety data indicate that serious adverse events, such as suicidality, aggression, and liver injury, are uncommon or rare . Additionally, atomoxetine does not have the abuse potential associated with stimulant medications, making it a safer option for long-term use Fu2022Simpson2004.
Dosage and Administration: Flexible Dosing Regimen
Atomoxetine can be administered either as a single daily dose or split into two evenly divided doses. The recommended dosage is weight-based, with adjustments made to achieve optimal therapeutic effects while minimizing side effects Fu2022Corman2004. For children and adolescents weighing less than 70 kg, the target dosage is 1.2 mg/kg/day, while for those weighing more than 70 kg and adults, the target dosage is 80 mg/day .
Conclusion: A Valuable Nonstimulant for ADHD Management
Atomoxetine represents a valuable treatment option for ADHD, particularly for patients who do not respond to or cannot tolerate stimulant medications. Its unique mechanism of action, combined with a favorable safety and tolerability profile, makes it an important addition to the therapeutic arsenal for managing ADHD across different age groups Kratochvil2003Fu2022Corman2004. As the first nonstimulant approved for ADHD, atomoxetine offers a promising alternative for effective symptom control without the risks associated with stimulant use.
Sources and full results
Most relevant research papers on this topic
Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial.
Atomoxetine and methylphenidate both show similar therapeutic effects and safety in children with ADHD, with no statistically significant differences observed.
Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder
Atomoxetine is a well-tolerated, nonstimulant medication for treating attention-deficit/hyperactivity disorder (ADHD) in children, adolescents, and adults.
Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder.
Atomoxetine, a selective inhibitor of noradrenergic uptake, effectively reduces ADHD symptoms in children and is well-tolerated.
Atomoxetine hydrochloride for the treatment of attention-deficit/hyperactivity disorder.
Atomoxetine hydrochloride is an effective and safe nonstimulant treatment for ADHD in pediatric and adult patients, offering an alternative to stimulants without the risk of addiction and abuse.
Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease
Atomoxetine is not effective in improving clinically significant depression in Parkinson's disease, but may improve global cognitive performance and daytime sleepiness.
Atomoxetine: the first nonstimulant for the management of attention-deficit/hyperactivity disorder.
Atomoxetine is a safe and well-tolerated non-stimulant for ADHD treatment in children, adolescents, and adults, offering an alternative option for those who do not respond to or cannot tolerate stimulants.
DOI